The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).
 
Lingzhi Hong
No Relationships to Disclose
 
Seyedeh Dibaj
No Relationships to Disclose
 
Marcelo Vailati Negrao
No Relationships to Disclose
 
Alexandre Reuben
No Relationships to Disclose
 
Emily Roarty
No Relationships to Disclose
 
Waree Rinsurongkawong
No Relationships to Disclose
 
Jeff Lewis
No Relationships to Disclose
 
Don Lynn Gibbons
Stock and Other Ownership Interests - Exact Sciences; Nektar
Consulting or Advisory Role - GlaxoSmithKline; Janssen Research & Development; Sanofi
Research Funding - AstraZeneca; Janssen Research & Development; Takeda
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; BerGenBio; Takeda
 
Boris Sepesi
No Relationships to Disclose
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - Abbvie; Araxes Pharma; ARIAD; Arrys Therapeutics; AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech; Genentech; Gritstone Bio; Janssen; Lilly; Loxo; Merck; Nektar; Novartis; Pfizer; Takeda; Tesaro; TRM Oncology
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; Roche
Other Relationship - Roche
 
Bonnie S. Glisson
Research Funding - Abbvie/Stemcentrx (Inst); Bristol-Myers Squibb (Inst); ISA Pharmaceuticals (Inst); Medimmune (Inst); Pfizer (Inst); Turnstone Bio (Inst)
Travel, Accommodations, Expenses - Abbvie/Stemcentrx; ISA Pharmaceuticals
 
George R. Blumenschein, Jr.
Consulting or Advisory Role - Abbvie; Adicet Bio; Amgen; ARIAD; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Merck; Novartis; Xcovery
Research Funding - Adaptimmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis; Genentech (Inst); GlaxoSmithKline (Inst); Immatics; Incyte; Kite, a Gilead company (Inst); Macrogenics (Inst); MedImmune; Merck (Inst); Novartis (Inst); Roche; Torque; Xcovery (Inst)
 
Phillip Andrew Futreal
Consulting or Advisory Role - GenePlus
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - AstraZeneca/MedImmune; Asuragen; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); OncoPlex Diagnostics (Inst); Pfizer (Inst); Silicon Biosytems (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; MSD Oncology; Pfizer
 
Jack A. Roth
No Relationships to Disclose
 
Stephen Swisher
Travel, Accommodations, Expenses - Ethicon
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Merck; Novartis; Spectrum Pharmaceuticals
Research Funding - AstraZeneca (Inst); Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
George R. Simon
Honoraria - AstraZeneca; Celgene
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Celgene; Genentech/Roche; Lilly; MD Anderson Physician’s Network; Merck Serono; Takeda
Speakers' Bureau - AstraZeneca; Celgene; DAVA Pharmaceuticals; Nexus Pharmaceuticals Inc; OncLive
Research Funding - Merck Sharp & Dohme
Travel, Accommodations, Expenses - ARIAD; AstraZeneca; Celgene; Genentech/Roche; Lilly; Merck Serono
 
J. Jack Lee
Consulting or Advisory Role - Abbvie
 
Jianjun Zhang
Honoraria - CancerNet; Geneplus; Innovent Biologics; Origimed; Roche; Sino-USA Biomedical Platform; Zhejiang Cancer Hospital
Consulting or Advisory Role - AstraZeneca; Capital Medical University; Geneplus
Research Funding - Merck